Human consumption

In several drug laws, human consumption is the legal threshold the control turns on — not a description of a substance's properties. A chemical offered for research or industrial use may sit outside a control even when it is pharmacologically active; the same chemical, once it is intended to be taken by a person, crosses into scheduled territory.

The phrase also appears on product packaging. When a seller prints "not for human consumption" on a label, the aim is to argue the intent test has not been met. Courts have consistently treated the label as one piece of evidence among many, not a conclusive defence.

What it means in practice

The United States Federal Analogue Act (21 U.S.C. § 813, enacted 1986) is the clearest example. Under that statute, a compound substantially similar in structure or pharmacology to a Schedule I or II substance is treated as Schedule I — but only when intended for human consumption. That conditional is what the "not for human consumption" label was designed to exploit in the market for novel psychoactive compounds.

In practice, courts have found intent through circumstantial evidence: consumer-oriented packaging, marketing language describing psychoactive effects, distribution through general retail channels, and online reviews from buyers describing drug effects. Repeated prosecutions have established intent despite the disclaimer.

The label also does nothing for substances already directly named on a schedule. When a compound is specifically listed, the consumption-intent gate does not apply — control attaches regardless of stated purpose.

How jurisdictions vary

The intent-for-human-consumption test is most closely associated with US federal law and with state analogue statutes that adopted similar language.

The United Kingdom took a different approach with the Psychoactive Substances Act 2016, in force from May 2016. That statute restricts the supply of substances capable of producing a psychoactive effect, without reference to stated purpose. A "not for human consumption" label offers no protection under it — capability, not intent, is the operative test.

Other jurisdictions control novel compounds through medicine licensing or public-health frameworks that do not use a consumption-intent gate at all. A label that carries legal weight in one country may be irrelevant in another.

What is contested

The label implies a distinction that forensic and clinical records do not consistently support. Products sold under the "not for human consumption" disclaimer — synthetic cannabinoids, synthetic cathinones, and other novel psychoactive compounds — have appeared in emergency-department presentations and post-mortem toxicology findings. The label describes a legal manoeuvre, not a pharmacological property, and carries no information about a sample's composition.

The "substantially similar" standard in the Federal Analogue Act has produced inconsistent outcomes across cases, with different courts accepting different structural and pharmacological comparisons. The standard has drawn criticism in legal commentary for vagueness, though courts have generally upheld it as applied.

Scope and currency

This entry describes how "human consumption" functions as a legal concept, principally in the context of US federal law. It is not legal advice and does not describe the law in any particular jurisdiction.

The position stated here reflects the law as of 2026. Laws change: substances are rescheduled, new statutes are enacted, and court interpretations evolve. The per-substance legal status section on each Psychedex substance page carries jurisdiction-specific information, a source, and a date — those are the values to rely on when the law in a specific place matters.